Summary
Psychedelics guidance from the FDA set to benefit developers, including AtaiBeckley, Jefferies says
The US Food and Drug Administration's finalized guidance on psychedelic drug development signals the agency remains receptive to helping developers navigate the approval process, a development that Jefferies said could benefit companies including Compass Pathways (NASDAQ:CMPS), AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC), Cybin Inc. (NYSE-A:CYBN, FRA:R7E), GH Research (NASDAQ:GHRS), Awakn Life Sciences (NEO:AWKN) and others in the sector. The firm wrote on Monday that the final guidance, alongside the FDA's plans to hold a public hearing on September 14, points to a more supportive regulatory environment that could reduce regulatory risk for psychedelic drug developers.
GH Research: Rapid Onset And Short Action Change The Treatment Paradigm
GH Research is advancing GH001, an inhalable mebufotenin therapy, in treatment-resistant depression. GH Research's Phase 2b data was strong, and a global Phase 3 program is expected in 2026. While the rapid onset and short psychedelic experience duration offered by GH001 are compelling it remains to be seen how the drug stacks up against peers under real-world conditions.
GH Research FY25 Results: Strong Cash Position As GH001 Advances Toward Phase 3
GH Research PLC remains well-capitalized with $280.7 million in cash, supporting its lead candidate GH001 for Treatment-Resistant Depression. GHRS's investment thesis centers on replicating strong Phase 2b efficacy for GH001 in a pivotal Phase 3 trial, with rapid, durable antidepressant effects and operational simplicity. The FDA has cleared GH001 for U.S. clinical investigation, positioning GHRS for a global Phase 3 program starting in 2026 without immediate capital constraints.
GH Research plc Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Didric Cederholm Lion Point Capital LP | 10,200 | $129,540 | $271,983 | $142,443 | 109.96% |
| MPM Mark P. Mennitt CenterBook Partners LP | 216,574 | $2.91M | $5.78M | $2.87M | 98.65% |
 Li Peng China Universal Asset Management Co. Ltd. | 13,507 | $176,162.9 | $360,096.62 | $183,933.72 | 104.41% |
 Christopher C. Powers Farther Finance Advisors, LLC | 100 | $1,472 | $2,871 | $1,399 | 95.04% |
 James B. Tananbaum Foresite Capital Management VI LLC | 315,492 | $4.44M | $9.04M | $4.6M | 103.77% |
GH Research plc (GHRS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has GH Research plc ever had a stock split?
GH Research plc Profile
| Biotechnology Industry | Healthcare Sector | Velichka Valcheva CEO | NASDAQ (NMS) Exchange | G3855L106 CUSIP |
| IE Country | 73 Employees | - Last Dividend | - Last Split | 25 Jun 2021 IPO Date |
Overview
GH Research PLC, along with its subsidiary GH Research Ireland Limited, is a pioneering company focused on advancing therapeutic solutions for psychiatric and neurological disorders. Established in 2018 and headquartered in Dublin, Ireland, the company has dedicated itself to developing innovative therapies, primarily using 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT). This compound is at the forefront of their research, aimed at addressing conditions such as treatment-resistant depression (TRD), and is being explored in various forms to maximize its therapeutic potential. GH Research PLC is committed to unveiling new avenues for enhancing mental health treatment, emphasizing the need for novel approaches in the face of challenging disorders.
Products and Services
GH001 (Inhalable Mebufotenin)
This lead product candidate of GH Research is in the form of an inhalable therapy, currently undergoing a Phase 2b clinical trial for treating patients with TRD. The innovative approach of GH001 leverages the potential benefits of 5-MeO-DMT in a convenient inhalable form, striving to offer a new hope for those battling treatment-resistant depression. Additionally, GH001 is in Phase 2a clinical trials for treating Bipolar II disorder and postpartum depression, indicating its versatile therapeutic potential across a range of psychiatric conditions.
GH002 (Intravenous Mebufotenin)
GH002 represents GH Research's endeavor in developing an intravenous (IV) mebufotenin product candidate. Currently in Phase 1 clinical trials, this form of therapy is designed for the IV administration to treat various psychiatric or neurological disorders. The development of GH002 showcases the company's commitment to exploring different delivery mechanisms for 5-MeO-DMT, aiming at broadening the therapeutic scope and accessibility for conditions requiring more direct or potent intervention strategies.
GH003 (Intranasal Mebufotenin)
Still in the early stages of development, GH003 is an intranasal mebufotenin product candidate. Focused on preclinical development, this therapy aims to utilize a nasal administration route to deliver treatment for psychiatric and neurological disorders. Aligning with the company's innovative ethos, GH003 explores another novel delivery system, potentially offering a less invasive and more patient-friendly option compared to IV administration, while maintaining the therapeutic efficacy of mebufotenin for targeting the central nervous system disorders.
